PRA Voted "Best CRO" in Asia

RALEIGH, N.C., March 25, 2013 /PRNewswire/ -- PRA, a leading clinical research organization, today announced it was voted "Best CRO" for the 3^rd annual BioPharma Asia Industry Awards 2013. The winner was announced March 19 at an awards dinner in Singapore.

"We are deeply honored to have been voted 'Best CRO'," said Kent Thoelke, PRA executive vice president, Scientific and Medical Affairs. "We have been working hard to continually meet the growing needs of our clients in this region, and I'm confident that we will continue to enhance our capability in the Asia Pacific region while ensuring we provide high-quality services."

"PRA has been strategically expanding its operations and has achieved several key expansion milestones in Asia Pacific," said Helen Neal, PRA director, Clinical Operations Asia Pacific. "We recently formed a joint venture with Wuxi PharmaTech in China, opened offices in Singapore, and expanded operations in South Korea."

Organized by Terrapinn, the awards honor and generate public recognition of the efforts, accomplishments and positive contributions of organizations and individuals in Asia's biopharmaceutical industry. They identify and reward those who demonstrate an ability to succeed, continually set standards of excellence, and who will be the future of the biopharmaceutical industry.

There are nine award categories: Best LSP Award; Best Contract Research Organization Award; Best Contract Manufacturing Organization Award; Most Innovative Asian Biotech Award; Asian Executive of the Year; Woman Executive of the Year; Best Manufacturing Solution Provider Award; Best Drug Pipeline Award; and Pharma Company of the Year.

About PRA

PRA is transforming clinical trials through our people, innovation and transparency. PRA provides personalized service customized to the unique requirements of each study. We support our global reach and innovative approach through flexible and reliable service, delivered by skilled employees dedicated to ensuring that sponsors achieve their long-term goals.

We serve our clients across all phases of pharmaceutical and biotech drug development by combining therapeutic and operational expertise with local knowledge. Offering services in 80+ countries and serving sponsors for 35+ years, we have amassed a level of expertise that has enabled us to work on a variety of compounds, ranging from niche treatments and therapies to blockbuster drugs. But at PRA, we are looking to the future, not the past. Our increasingly forward-thinking approach to transforming the clinical trial landscape will continue to make a difference to healthcare patients around the world.

To learn more about PRA, please visit praintl.com, email [email protected] or call our Global Headquarters.

SOURCE PRA International